Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
2002
Effects of ERBB2 amplicon size and genomic alterations of chromosomes 1, 3, and 10 on patient response to trastuzumab in metastatic breast cancer
2007
Mechanisms of Endocrine Resistance in Breast Cancer
2010
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Spontaneous and pronase‐induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines
2012
HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study
2002
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment
2009
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
2006
Hepatocellular carcinoma
2016 Standout
Role of platelet-derived growth factors in physiology and medicine
2008 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Tumor targeting using anti-her2 immunoliposomes
2001
EGF–ERBB signalling: towards the systems level
2006 Standout
Attitudes to vaccination: A critical review
2014 Standout
Recent advances with liposomes as pharmaceutical carriers
2005 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
2010 Standout
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
2005 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Issues and barriers to development of clinically useful tumor markers: A development pathway proposal
2002
Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis
2003
The hallmarks of cancer
2012 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
2015
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
1999 Standout
Environmental oestrogens and human reproductive cancers
1998
The Politics of Personalised Medicine: Pharmacogenetics in the Clinic
2004
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Works of MF Press being referenced
The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer.
1999
Evaluation of chromosome 17 (Chr-17) polysomy in HER2 FISH-negative metastatic breast cancer (MBC) patients enrolled in a randomized phase III study of paclitaxel and lapatinib
2008
Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptor.
1993
Lapatinib and paclitaxel in HER2-negative, extracellular domain (ECD) positive metastatic breast cancer (MBC) in a randomized phase III study
2008
Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.
2011
Association of topoisomerase II-alpha (TOP2A) gene amplification with responsiveness to anthracycline-containing chemotherapy among women with metastatic breast cancer entered in the Herceptin H0648g pivotal clinical trial
2005
Correlation of HER2 gene amplification, HER2 and EGFR expression (protein and mRNA) with lapatinib efficacy in women with metastatic breast cancer
2008
Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008
2009